Yanfei Liu

Yanfei Liu

Auto-generated profile, based on publicly available information

Yanfei Liu

Department of Clinical Laboratory, Hangzhou Women’s Hospital 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2024 in Health Science Reports
Verified
Journal Article
Open access
CJChen Jiang
Chen Jiang
HWHaiyan Wen
Haiyan Wen
THTingting Hu
Tingting Hu
YLYanfei Liu
Yanfei Liu
XDXiaoqing Dai
Xiaoqing Dai
YCYiming Chen
Yiming Chen
Background and Aims: The prevalence of gestational diabetes mellitus (GDM) continues to increase, and the phenomenon of women giving birth at an older age is becoming more common worldwide. Less is known abouts the impact of GDM combined with advanced maternal age (AMA) on pregnancy outcomes. To explore the impact of AMA complicated with GDM on pregnancy outcomes. Methods: This study included 34,602 pregnancies between 2018 and 2020 in Hangzhou, China. The pregnant women were divided into four groups according to advanced age (≥35 years) and GDM as follows: AMA women without GDM (non‐AGDM) group ( n = 2614), young pregnant women with GDM (YGDM) group ( n = 4016), AMA women with GDM (AGDM) group ( n = 850), and young pregnant women without GDM (non‐YGDM) group ( n = 27,122). Univariate analysis was carried out by Mann–Whitney U test or Pearson's χ 2 test. Multivariate logistic regression analysis was used to investigate the effect of AMA and GDM on pregnancy outcomes. Results: Multivariate logistic regression analysis showed that in the comparison against non‐YGDM garoup, the ORs of fetal chromosome abnormality, parity, urgent cesarean section, gravidity, scheduled cesarean section, body mass index (BMI) ≥30 kg/m 2 , pre‐eclampsia, thrombocytopenia, hyperlipidemia, BMI 25–29.9 kg/m 2 , blood urea nitrogen, fasting blood glucose, and creatinine in AGDM group were 16.044, 4.284, 3.530, 3.284, 3.257, 2.049, 1.935, 1.898, 1.690, 1.471, 1.304, 1.216, and 1.026 (all p < 0.05). Conclusions: The prevalence of pregnant women with AGDM was 2.46% in Hang Zhou, China. The increasing gravidity of AMA women was related to a greater risk of GDM. The AGDM group associated with a greater risks of chromosomal abnormality in offspring and cesarean section, especially urgent cesarean section.

24 January 2025 in Endocrine Connections
Verified
Journal Article
Open access
PDF file
ZWZhen Wang
Zhen Wang
XTXiaojing Teng
Xiaojing Teng
YSYonghai Shen
Yonghai Shen
YLYanfei Liu
Yanfei Liu
Background: The aim is to develop age-specific anti-Müllerian hormone (AMH) screening criteria for polycystic ovary syndrome (PCOS) to facilitate early detection and diagnosis of the condition and subsequently evaluate the screening criteria. Methods: A retrospective analysis was performed on patient data from Hangzhou Women’s Hospital between July 2021 and August 2024. The use of restricted cubic spline analysis helped identify age-related inflection points, which were crucial for segmenting the patient population. Statistical analysis was conducted using SPSS software, and the receiver operating characteristic curve was employed to determine the area under the curve, optimal AMH screening thresholds, sensitivity, specificity, Youden index, correct diagnosis rate, positive predictive value and negative predictive value. The established age-related AMH screening criteria for PCOS were then validated using a separate validation group. The consistency of the PCOS age-related AMH screening test with the 2003 Rotterdam PCOS diagnostic criteria was assessed using the kappa statistic. Results: The derived age-specific AMH screening thresholds for PCOS are as follows: ≥6.93 ng/mL (20–27 years old), ≥5.06 ng/mL (28–30 years old) and ≥4.19 ng/mL (31–39 years old). Conclusion: The age-stratified AMH screening criteria demonstrated high sensitivity, specificity and accuracy in identifying PCOS, indicating a strong predictive value. However, the development of more robust and universally applicable diagnostic criteria for PCOS will require additional multicenter, prospective clinical trials for further validation.